Inventiva ADRIVA
Price$3.46Intrinsic value$4.4529% above price

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $9.5M-50.8% YoYTTM through 30 Jun 2025
Net Income -$190.7MTTM through 30 Jun 2025
Free Cash Flow -$101.3MTTM through 30 Jun 2025

Margins

Current
Operating Margin-1,060.6%
Net Margin-2,002.7%

Returns

-182.0%ROE
-132.6%ROA

Balance Sheet Health

Current Ratio2.96x
Cash & Equivalents$122.1M

Quality Metrics

FCF Margin-1,063.8%

Multi-Year Trend

Revenue
'18'19'20'21'22'23'24
FY2024: $9.2M
Diluted EPS
'19'20'21'22'23'24
FY2024: $-3.08

Dividend

No dividend

Segment Performance

SegmentRevenueYoYOutlook
Service delivery and clinical stage research$4.5M-51.3%
View details

Topline results from Phase 3 NATiV3 trial expected in Q4 2026

Financials converted at 0.8484 from EUR.
All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.